Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) reported that on July 1, 2026 its Compensation Committee granted restricted stock units covering 951 shares of common stock to five new non-executive employees under its 2024 Inducement Plan, with vesting in four equal annual installments, in line with Nasdaq Listing Rule 5635(c)(4).

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – PRAX

-1.58%

-1.58% News Effect

On the day this news was published, PRAX declined 1.58%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The company added 951 inducement RSUs for 5 new hires under its 2024 Inducement Plan, continuing a p...

Analysis

The company added 951 inducement RSUs for 5 new hires under its 2024 Inducement Plan, continuing a pattern of routine equity-based compensation. Investors may watch how cumulative grants interact with moderate short positioning and recent insider selling trends.

Key Figures

Inducement RSUs granted: 951 shares New employees: 5 employees Vesting schedule: 4 annual installments

3 metrics

Inducement RSUs granted 951 shares Aggregate awards to five new non-executive employees under 2024 Inducement Plan

New employees 5 employees Recipients of inducement restricted stock unit awards

Vesting schedule 4 annual installments RSUs vest over four years, contingent on continued employment

Historical Context

5 past events · Latest: Jun 29 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 29	Regulatory review delay	Negative	-4.5%	FDA extended relutrigine NDA review and delayed PDUFA target action date.
Jun 22	Breakthrough designation	Positive	+6.7%	FDA granted Breakthrough Therapy Designation for elsunersen in SCN2A-DEE seizures.
Jun 04	Conference participation	Neutral	-4.1%	Company scheduled a corporate overview at a major healthcare conference.
Jun 02	Inducement equity grants	Neutral	+8.1%	Inducement RSUs for 2,754 shares granted to thirteen new non-executive employees.
Jun 01	Trial outcome update	Negative	-23.0%	Vormatrigine Phase 2/3 trial missed primary endpoint; program reassessment announced.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent headlines with clearly positive or negative clinical or regulatory outcomes tended to see aligned price moves, while routine or administrative items, including prior inducement grants and conference updates, sometimes produced divergent reactions.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), equity awards, inducement plan

4 terms

restricted stock unit financial

"granted restricted stock unit awards covering an aggregate of 951 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity awards financial

"used exclusively for the grant of equity awards to individuals who were not previously employees"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

inducement plan financial

"under the Praxis Precision Medicines, Inc. 2024 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on July 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 951 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com 
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com 
617-430-7576

FAQ

What inducement grants did Praxis (PRAX) announce on July 2, 2026?

Praxis announced restricted stock unit awards covering 951 shares for five new non-executive employees. According to Praxis, these RSUs were granted under the 2024 Inducement Plan as employment inducements consistent with Nasdaq Listing Rule 5635(c)(4).

How many Praxis (PRAX) shares are covered by the July 2026 inducement RSU grants?

The July 2026 inducement RSU grants cover an aggregate of 951 Praxis common shares. According to Praxis, these awards went to five new non-executive employees under the 2024 Inducement Plan as material inducements to accept employment.

Who received the July 1, 2026 Praxis (PRAX) inducement RSU awards?

Five new non-executive employees received the July 1, 2026 Praxis inducement RSU awards. According to Praxis, the grants were made under the 2024 Inducement Plan as material inducements for these individuals to enter into employment with the company.

How do the Praxis (PRAX) July 2026 inducement RSUs vest?

The July 2026 Praxis inducement RSUs vest in four equal annual installments. According to Praxis, vesting is subject to each employee’s continued employment with the company on the applicable vesting dates over the four-year schedule.

What is the Praxis 2024 Inducement Plan and how is it used for PRAX employees?

The Praxis 2024 Inducement Plan is used exclusively for equity awards to new hires or rehires. According to Praxis, such grants serve as material inducements to enter employment, consistent with Nasdaq Listing Rule 5635(c)(4).

How does Nasdaq Listing Rule 5635(c)(4) relate to Praxis (PRAX) inducement grants?

Nasdaq Listing Rule 5635(c)(4) governs Praxis’s use of inducement equity awards for new employees. According to Praxis, the 2024 Inducement Plan grants, including the July 1, 2026 RSUs, are made as employment inducements in accordance with this rule.